drugset / Trial / NCT05603884
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 2
Recruiting
66 enrolled
The First Affiliated Hospital of Xiamen University
CSPC Pharmaceutical Group Limited · collabChipscreen Biosciences, Ltd. · collabFujian Cancer Hospital · collabFujian Provincial Hospital · collabHuizhou Municipal Central Hospital · collabJieyang People's Hospital · collabZhangzhou manicipal hospital of Fujian Province · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Timeline
- Start
- 2022-12-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | — |
| Subject | Cytarabine | Small molecule | 10 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 20 mg | — |
| Subject | Tucidinostat | Small molecule | 30 mg | — |
| Subject | Venetoclax | Small molecule | 200 mg | — |
| Subject | dicitabine | Unknown | 25 mg | — |